Healthcare Industry News: retractor
News Release - July 10, 2007
Interventional Spine, Inc. Appoints Todd M. Clearwater, Senior Vice President of SalesIRVINE, Calif.--(HSMN NewsFeed)--Interventional Spine, Inc., a privately held medical device manufacturer focusing on diseases of the spine, today announced the appointment of Todd M. Clearwater to the newly created position of Senior Vice President of Sales. He will oversee the building and expansion of sales activities in the United States.
"Interventional Spine is pleased to appoint a senior executive with extensive experience in the orthopedic device industry. We intend to call upon Todd's 12 years of experience, and to capitalize on his strengths in strategic planning, program development and sales results. His proven ability to build and lead sales teams will benefit our organization as we continue to grow," said Walter A. Cuevas, Chief Executive Officer.
"I am acutely aware of the excellent opportunity at Interventional Spine, especially knowing that they are the only company in the spine market that offers a percutaneous method of providing spinal stabilization as a component of spinal fusion procedures," said Mr. Clearwater.
Prior to joining Interventional Spine, Mr. Clearwater most recently was the Regional Sales Manager for Kyphon, Inc. Previously, Mr. Clearwater also served as Director of Sales of the Spine Education Program while at Kyphon, Inc. In addition, Mr. Clearwater has held various sales management positions within the medical device and pharmaceutical industries.
PERPOS(TM) PLS System
The Perpos(TM) PLS System with its BONE-LOK® PLS Implant utilizes the CLASP® custom compression fit technology to achieve facet-to-pedicle fixation, with percutaneous access through the Teleport® Tissue retractors.
The Perpos(TM) PLS System with its BONE-LOK(TM) PLS Implant has been granted FDA 510(k) clearance, and has begun generating 2007 revenues for the Company in the United States.
The PercuDyn(TM) System will undergo a Pre-Market Approval ("PMA") process with the FDA. The Company has submitted an Investigation Device Exemption ("IDE") to the FDA in June of 2007.
PercuDyn(TM) has been engineered to complement the features of Interventional Spine's Teleport® Tissue retractor, another proprietary Company technology, and is an integral part of a percutaneous implant methodology that has been designed and qualified to advance the current clinical state of the art for the widest possible number of patients.
Interventional Spine, Inc. is a privately held company based in Irvine, California that designs, develops, and markets patented implantable devices for the spine that can be deployed via percutaneous techniques, supported by the Company's unique product introduction systems, providing benefits to patients, surgeons, and. hospitals. More information on the Company and its products can be found at: www.i-spineinc.com.
Source: Interventional Spine
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.